Key Development In response to voter inquiries regarding the limited availability of insured pharmaceuticals at primary healthcare facilities, Minister of... Read more
Category: Uncategorized
Municipal Healthcare Regulatory Enforcement: Hai Phong Identifies 302 Unlicensed Medical Facilities, Mandating National Data Digitization by August 31, 2026
Key Development The Hai Phong Department of Health has officially released the results of a comprehensive municipal healthcare audit, identifying... Read more
Regional Healthcare Export Modernization: Ministry of Health Releases Draft Medical Tourism Master Plan 2026–2030, Targeting 750,000 International Patients and $2.5 Billion Revenue
Key Development This morning, August 12, 2026, the Ministry of Health (MOH) of Vietnam formally initiated public and stakeholder consultations... Read more
Vulnerable Healthcare Infrastructure Expansion: Ho Chi Minh City Plans New 2,000-Bed Psychiatric Hospital and Rehabilitation Complex, Directing Emergency Relocation of Pediatric Care Units
Key Development On the morning of August 11, 2026, a delegation from the Ho Chi Minh City Party Committee led... Read more
Expanding Ophthalmic Biosimilar Footprint: Samsung Bioepis Officially Launches Opuviz® (Aflibercept Biosimilar) Pre-Filled Syringe Across Europe
Key Development South Korean biopharmaceutical major Samsung Bioepis Co., Ltd. officially announced the commercial availability of the pre-filled syringe (PFS)... Read more
Domestic Biomanufacturing Infrastructure Expansion: Bristol Myers Squibb Selects Houston’s Generation Park for $2.3 Billion Multi-Modal Manufacturing Campus
Key Development Biopharmaceutical major Bristol Myers Squibb (NYSE: BMY) has officially selected Generation Park in Houston, Texas, as the site... Read more
Domestic Biomanufacturing Expansion: Bristol Myers Squibb Commits $2.3 Billion to Build High-Tech Manufacturing Campus in Houston, Texas
Key Development American biopharmaceutical leader Bristol Myers Squibb (NYSE: BMY) has officially announced a $2.3 billion investment to construct a... Read more
Greater China Commercial Expansion: Innovent Biologics and Daiichi Sankyo Sign Exclusive Commercialization Agreement for Vanflyta® in China
Key Development Biopharmaceutical major Innovent Biologics, Inc. (HKEX: 1801) and Japanese pharmaceutical company Daiichi Sankyo Company, Limited (TSE: 4568) have... Read more
Rare Oncology Licensing Agreement: Sobi Secures Global Rights to Innate Pharma’s Lacutamab in Up to $580 Million Deal Targeting Cutaneous T-Cell Lymphoma (CTCL)
Key Development Swedish rare disease specialist Swedish Orphan Biovitrum (Sobi) has executed an exclusive global licensing agreement valued at up... Read more









